Literature DB >> 8871161

Systemic ciclosporin A in high-risk keratoplasties.

T Reinhard1, R Sundmacher, P Heering.   

Abstract

BACKGROUND: It was the purpose of this study to compile the results of all high-risk keratoplasties (kp) performed in our hospital under systemic ciclosporin A (Ci A) cover from 1987 through 1994.
METHODS: One hundred and thirty-one keratoplasties were performed. Ci A was administered for an average period of 9.4 months. We aimed at trough levels of 100-150 ng/ml (monoclonal RIA/TDx). The 29 kp in group A were second or third repeat kp and/or the recipient cornea had severe deep vascularization in all quadrants and/or a transplant position at the limbus was inevitable (expected risk: only immune reactions). The 40 kp in group B were threatened by severe ocular surface disorders (without severe limbal stem cell insufficiency) and by immune reactions (atopic keratopathy, keratoconus with severe endogenous eczema or chronic blepharokeratoconjunctivitis). In the 45 kp of group C resurfacing problems from severe limbal stem cell insufficiency and immune reactions were anticipated (severe burns, pseudopemphigoid or Lyell syndrome). Group D comprised 17 kp with various diagnoses (e.g. kp in newborns, rheumatic and Acanthamoeba keratitis).
RESULTS: In group A 91% of the grafts were clear 2 years postoperatively, in group B 76%, in group C 38% and in group D 18%. In 32 of 41 failed grafts (78%), resurfacing problems were the only reason for or participated in final graft failure. Immune reactions and other causes of graft failure were of minor importance.
CONCLUSIONS: (1) Systemic Ci A cover can efficiently suppress immune reactions. (2) With the suppression of immune reactions, resurfacing disorders become the most important single cause for functional graft failure. (3) For eyes with a considerable loss of limbal stem cells, limbal stem cell transplantation should be combined with systemic Ci A cover in order to improve the long-term prognosis for penetrating keratoplasty.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871161     DOI: 10.1007/bf02343059

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  35 in total

1.  Corneal epithelial wound healing in the absence of limbal epithelium.

Authors:  A J Huang; S C Tseng
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-01       Impact factor: 4.799

2.  Comparison of RFLP-DR beta and serological HLA-DR typing in 1500 individuals.

Authors:  J Mytilineos; S Scherer; G Opelz
Journal:  Transplantation       Date:  1990-11       Impact factor: 4.939

3.  Central corneolimbal transplantation under systemic ciclosporin A cover for severe limbal stem cell insufficiency.

Authors:  R Sundmacher; T Reinhard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

4.  Histocompatibility testing for keratoplasty in high-risk patients.

Authors:  G N Foulks; F P Sanfilippo; J A Locascio; J M MacQueen; D V Dawson
Journal:  Ophthalmology       Date:  1983-03       Impact factor: 12.079

5.  Penetrating keratoplasty in the rat: a model for the study of immunosuppressive treatment of graft rejection.

Authors:  C P Herbort; M Matsubara; M Nishi; M Mochizuki
Journal:  Jpn J Ophthalmol       Date:  1989       Impact factor: 2.447

6.  [Preventive systemic cyclosporin A in risk keratoplasty].

Authors:  V Rossa; R Sundmacher; P Heering
Journal:  Klin Monbl Augenheilkd       Date:  1990-12       Impact factor: 0.700

7.  HLA-B and -DR match reduces the allograft reaction after keratoplasty.

Authors:  F Hoffmann; M Tregel; W Noske; S Bünte
Journal:  Ger J Ophthalmol       Date:  1994-03

8.  The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1992-10

9.  [Kidney function of patients with healthy kidneys during cyclosporin treatment].

Authors:  P Heering; B Kutkuhn; G Kreuzpaintner; T Reinhard; R Sundmacher; B Grabensee
Journal:  Klin Wochenschr       Date:  1991-11-26
View more
  15 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Penetrating keratoplasty: outcomes from a corneal unit compared to national data.

Authors:  P Beckingsale; I Mavrikakis; N Al-Yousuf; E Mavrikakis; S M Daya
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

Review 3.  [Perspectives and current state in limbal stem cell transplantation].

Authors:  P Eberwein; T Reinhard
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

4.  The influence of glaucoma history on graft survival after penetrating keratoplasty.

Authors:  T Reinhard; C Kallmann; A Cepin; E Godehardt; R Sundmacher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-09       Impact factor: 3.117

Review 5.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 6.  Systemic cyclosporine and corneal transplantation.

Authors:  Mohammed Ziaei; Fatemeh Ziaei; Bita Manzouri
Journal:  Int Ophthalmol       Date:  2016-02       Impact factor: 2.031

7.  Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty.

Authors:  Jong Joo Lee; Mee Kum Kim; Won Ryang Wee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-21       Impact factor: 3.117

8.  Clear graft survival and immune reactions following emergency keratoplasty.

Authors:  P Maier; D Böhringer; T Reinhard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.117

Review 9.  [Ocular surface reconstruction in limbal stem cell insufficiency: transplantation of limbal tissue].

Authors:  P Eberwein; T Reinhard
Journal:  Ophthalmologe       Date:  2012-09       Impact factor: 1.059

10.  [Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty].

Authors:  N Bailly; I Dunewa; P Schlattmann; P W Rieck
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.